GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
Executive Summary
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
You may also be interested in...
Future Vaccine Growth Could Come From Recent Biotech Entrants – Tufts
The potential to create novel, innovative products has made the vaccine market more attractive in recent years, drawing new entrants as well as a resurgence of interest from traditional vaccine manufacturers, Tufts Center for the Study of Drug Development Director Kenneth Kaitin suggests
Future Vaccine Growth Could Come From Recent Biotech Entrants – Tufts
The potential to create novel, innovative products has made the vaccine market more attractive in recent years, drawing new entrants as well as a resurgence of interest from traditional vaccine manufacturers, Tufts Center for the Study of Drug Development Director Kenneth Kaitin suggests
Collaboration Deals With Pharma May Be Preferable To Licensing For Biotech
Biotechs may want to look at deal structures with pharmaceutical companies outside of the traditional licensing model in order to have greater control over the development process, Medarex Senior Director of Development Melinda Shockley said at the recent Drug Information Association annual meeting in Philadelphia